The trial, called SELECT, was conducted in 41 countries with more than 17,000 people who were overweight or obese and at high cardiovascular risk but who didnt have diabetes
Novo and its biggest rival in the obesity drug market, Eli Lilly, sued several medical spas, weight-loss clinics and compounding pharmacies last year to stop them from selling products purporting to contain the active ingredients
Exendin-4, a glucagon-like peptide-1 receptor agonist, provides neuroprotection in mice transient focal cerebral ischemia
The main difference is the specific GLP-1 receptor agonist they contain
It contains vitamin C that helps boost the natural synthesis of Glutathione in our body, thus enhancing immunity and better bioavailability
It activates GLP-1 receptors that signal feelings of fullness, while GIP receptors enhance insulin regulation